Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL

Estrella Immunopharma, Inc.

First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.
Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).
Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).
Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.
Clinical trial identifier on ClinicalTrials.gov: NCT06343311.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.